- Home
- FINS vs MYGN Comparison
FINS vs MYGN Comparison
Compare FINS & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FINS | MYGN |
|---|---|---|
| Founded | N/A | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 436.4M | 481.6M |
| IPO Year | 2018 | 1996 |
Fundamental Metrics
Financial Performance| Metric | FINS | MYGN |
|---|---|---|
| Price | $12.89 | $5.10 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $8.06 |
| AVG Volume (30 Days) | 80.7K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | N/A | $7.19 |
| Revenue Next Year | N/A | $5.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $12.21 | $3.76 |
| 52 Week High | $13.64 | $11.44 |
Technical Indicators
Market Signals| Indicator | FINS | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 21.83 | 50.70 |
| Support Level | $12.84 | $5.02 |
| Resistance Level | $13.26 | $5.67 |
| Average True Range (ATR) | 0.11 | 0.39 |
| MACD | -0.04 | 0.10 |
| Stochastic Oscillator | 15.69 | 61.80 |
Price Performance
Historical ComparisonAbout FINS Angel Oak Financial Strategies Income Term Trust of Beneficial Interest
Angel Oak Financial Strats Income Term is a non-diversified, closed-end management investment company. The fund's objective is to seek current income with a secondary objective of total return. In pursuing its investment objective, the fund invests mainly in debt issued by financial institutions, including subordinated debt, unrated debt, senior debt, and high-yield securities.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.